INTRODUCTION {#s0}
============

The pervasiveness of fungi and their impact on globally important processes can be seen in the evolution of the human immune system ([@B1]), the chemistry of soil ([@B2]), the genomes of plants ([@B3], [@B4]), and even the progression of climate change ([@B5]). Fungi interact extensively with plants, animals, bacteria, and other organisms; these relationships range from mutualists to saprotrophs to pathogens. The influence of fungi across of variety of biological processes has its roots in the massive degree of diversity within the kingdom of fungi. Fungi are characterized by varied morphologies, diverse growth strategies, and assorted nutrient acquisition capabilities. Though only roughly 100,000 species of fungi are accepted in the current taxonomy ([@B6]), it is estimated that there exist on the order of 1.5 million fungal species and that up to one-quarter of the world's biomass is of fungal origin ([@B7], [@B8]). Our imperfect understanding of fungal diversity arises from the lack of taxonomically relevant morphological features and pleomorphisms of fungi, the difficulty or impossibility of culturing many fungi isolated from natural environments, and the inability to consistently identify diagnostic sexual structures in fungi grown in culture or observed in the environment. The great ecological success of fungi, either as filamentous or unicellular growth forms, is a testament to their diversity and functional importance in the global ecosystem.

Understanding the dimensions of fungal diversity has major implications for disease control, crop management, and decomposition of both recalcitrant organic and synthetic materials. For environmental, agricultural, and biomedical purposes, we need agents that target fungi broadly. The innate immune response to infection by fungi and other microbes includes production of host defense peptides (HDPs), and these molecules offer clues for development of synthetic antifungal agents. HDPs have diverse sequences. Many of these peptides are relatively short (10 to 50 amino acid residues) and adopt globally amphiphilic conformations, although the nature of these conformations is variable (α-helix versus β-sheet versus irregular) ([@B9]). HDP amphiphilicity is hypothesized to be critical for disruption of microbial membranes, which results in either microbial killing or inhibition of growth (other antimicrobial mechanisms of action have been proposed as well) ([@B10], [@B11]).

Since their discovery in the 1980s, HDPs and their synthetic analogs have been subjects of interest as potential therapeutic agents. The high cost of production and inherent toxicity to the host manifested by HDPs, however, have discouraged clinical development of these peptides thus far ([@B9]). The production challenge has encouraged evaluation of random copolymers with hydrophilic and lipophilic subunits for antimicrobial activity ([@B12][@B13][@B18]). Random copolymers can be synthesized in a more economical manner than can sequence-specific peptides.

Nylon-3 polymers have been studied as antibacterial agents since 2007, and more recently, examples with both antibacterial and antifungal activities have been reported ([@B19][@B20][@B23]). Nylon-3 polymers are synthesized via the anionic ring-opening polymerization of β-lactams. Use of racemic β-lactams leads to heterochiral polymer chains. The protein-like polyamide backbone of nylon-3 polymers is believed to confer biocompatibility, while the presence of β-amino acid subunits renders these materials resistant to proteolytic degradation ([@B24]).

Three nylon-3 polymers have previously been shown to have activity against pathogenic fungi ([@B20], [@B22]). These polymers, designated MM-TM, DM-TM, and NM ([Fig. 1](#fig1){ref-type="fig"}), inhibit the growth of Candida albicans and Cryptococcus neoformans, pathogenic fungi with yeast morphology, as single agents. In contrast, these polymers were able to halt the growth of the pathogenic, filamentous Aspergillus fumigatus only when applied in combination with established azole-based antifungal agents; the polymers were not active as single agents. The activity of MM-TM, DM-TM, and NM against pathogenic yeasts led us to hypothesize that these polymers might be active against a wide range of unicellular yeasts, but not against filamentous fungi. The work described here presents a test of this hypothesis. We have undertaken, to our knowledge, the broadest phylogenetically susceptibility analysis of any antifungal compound to determine the extent of activity of the MM-TM, DM-TM, and NM polymers. We expanded our evaluation to include a diverse array of both filamentous and nonfilamentous species across the fungal kingdom, including members of the *Zygomycetes*, *Ascomycetes*, and *Basidiomycetes* phyla. Surprisingly, most fungi tested, including those naturally resistant to current antifungal drugs, were sensitive to the nylon-3 polymers, which raises the possibility that nylon-3 polymers could be useful against pathogens for which there are only limited and/or no antifungal agents available at present.

![Nylon-3 copolymers employed in this study. All three polymers are heterochiral. *t*Bu, *tert*-butyl.](sph0031825510001){#fig1}

RESULTS {#s1}
=======

NM, MM-TM, and DM-TM are active at low concentrations against phylogenetically diverse yeasts. {#s1.1}
----------------------------------------------------------------------------------------------

To evaluate the antifungal activity of MM-TM, DM-TM, and NM against six species of vegetatively growing yeasts across three different genera, we used the CLSI M27-A3 broth microdilution method ([Table 1](#tab1){ref-type="table"}) ([@B25]). Polymers were evaluated by measuring MICs (MIC~100~s). For comparison, we also evaluated the commonly used antifungal drug fluconazole (FLC) in terms of MIC~50~ (the MIC to halt 50% of growth per the CLSI M27-A3 standard). All of the yeasts tested were sensitive to all three of the nylon-3 polymers, including those strains resistant to azoles. The polymers were particularly effective against *Cryptococcus* spp. (Cryptococcus neoformans and Cryptococcus amylolentus) of the *Basidiomycota* phylum, exhibiting MIC~100~ values from 2 to 4 µg/ml, which is comparable to or better than concentrations of fluconazole required to halt only 50% of fungal growth. MM-TM, DM-TM, and NM were also active against two genera within the *Ascomycota* phylum: *Candida* and *Saccharomyces*. Saccharomyces cerevisiae was particularly sensitive to all three nylon-3 polymers, with NM being the most active (MIC = 2 µg/ml) and DM-TM the least active (MIC = 8 µg/ml). *Candida* spp. were also susceptible to the polymers, with MIC~100~ values for *Candida albicans* and *Candida krusei* generally ranging from 4 to 16 µg/ml. The polymers were also active against *Candida auris*. Invasive and drug-resistant C. auris infections have been increasingly reported in health care facilities around the world ([@B26], [@B27]). The two strains of C. auris tested both showed sensitivity (MIC~100~s of 4 to 16 µg/ml) to all three polymers, with particular sensitivity to NM. Overall, yeasts were highly susceptible to the three nylon-3 polymers tested for efficacy, with NM being the most active polymer against yeasts.

###### 

MIC results for MM-TM, DM-TM, and NM against vegetatively growing yeasts

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Species[^a^](#ngtab1.1){ref-type="table-fn"}   Isolate                                   Resistance                                 MIC~100~ (µg/ml)[^b^](#ngtab1.2){ref-type="table-fn"}   FLU MIC~50~\                                        
                                                                                                                                                                                              (µg/ml)[^c^](#ngtab1.3){ref-type="table-fn"}        
  ---------------------------------------------- ----------------------------------------- ------------------------------------------ ------------------------------------------------------- ---------------------------------------------- ---- ------
  Saccharomyces cerevisiae                       W303                                                                                 2                                                       4                                              8    \<1

                                                                                                                                                                                                                                                  

  Cryptococcus neoformans                        CN1                                                                                  4                                                       4                                              4    4

                                                 CN2                                       FLU                                        4                                                       4                                              4    \>64

                                                 CN3                                       FLU                                        4                                                       4                                              4    \>64

                                                                                                                                                                                                                                                  

  Cryptococcus amylolentus                       CBS 6273                                                                             4                                                       4                                              2    16

                                                 CBS 6039                                                                             4                                                       4                                              4    16

                                                                                                                                                                                                                                                  

  Candida albicans                               ATCC 90028                                                                           4                                                       4                                              4    1

                                                 SC5314                                                                               8                                                       16                                             16   0.25

                                                 CA3                                       Azole                                      8                                                       16                                             64   \>64

                                                                                                                                                                                                                                                  

  Candida krusei                                 QC[^e^](#ngtab1.4){ref-type="table-fn"}                                              4                                                       16                                             8    32

                                                                                                                                                                                                                                                  

  Candida auris                                  B11220                                                                               4                                                       8                                              8    4

                                                 C54039                                    AMB[^d^](#ngtab1.5){ref-type="table-fn"}   8                                                       16                                             16   16
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Candida lusitaniae was tested previously ([@B23]) for MIC activity with MM-TM and shown to have an MIC~100~ of 5 µg/ml.

MIC~100~, MIC resulting in 100% reduction in growth.

FLU, fluconazole; MIC~50~, MIC resulting in 50% reduction in growth.

AMB, amphotericin B.

QC, quality control.

The *Aspergillus* genus is generally insensitive to nylon-3 polymers, NM, MM-TM, and DM-TM. {#s1.2}
-------------------------------------------------------------------------------------------

Previous reports show that nylon-3 polymers are largely inactive against the pathogenic fungus Aspergillus fumigatus ([@B22]). To determine whether this resistance phenotype was specific to A. fumigatus, we assessed the antifungal activity of MM-TM, DM-TM, and NM against 18 different species within the *Aspergillus* genus. For 6 of the 18 *Aspergillus* species examined, none of the three polymers caused any decrease in hyphal growth relative to a no-treatment control ([Table 2](#tab2){ref-type="table"}, boldface rows, rows 1 to 7). A. fumigatus, A. flavus, and A. terreus are considered to be the most pathogenic species of the *Aspergillus* genus ([@B28]). It seems possible that the high pathogenicity of these three species is related to their relatively high resistance to the nylon-3 polymers tested. The remaining 12 species of *Aspergillus* evaluated showed low levels of growth inhibition, with MIC~100~s ranging from 8 to \>64 µg/ml, with the DM-TM copolymer demonstrating the most promising antifungal activity among the three nylon-3 polymers. While all 18 species of *Aspergillus* were tested according to CLSI M38-A2 methodology (conidia in liquid culture), four species, selected for their varied response to polymer, were also tested for susceptibility to polymer as hyphal clumps in liquid culture. MIC~100~ values against hyphal fragments were determined as the concentration of agent required to prevent hyphal growth, monitored as an increase in optical density at 600 nm (OD~600~), after incubation at 35°C for 48 h. Three of these species, A. fumigatus, A. terreus, and A. flavus, were highly resistant to polymer as conidia, and their hyphal fragments were also insensitive to polymer. The conidia of the fourth species of *Aspergillus* selected, A. nidulans, were susceptible to polymer, with MIC~100~ values ranging from 8 to 16 µg/ml; however, polymer activity was diminished when incubated with A. nidulans hyphal clumps (MIC~100~ values of 32 to \>64 µg/ml). As expected from precedent, the efficacy of itraconazole against *Aspergillus* species as hyphal clumps was also greatly diminished relative to treatment of conidia (MIC~100,conidia~ \~ 1 µg/ml; MIC~100,hyphae~ \~8 to \>64 µg/ml) ([@B29]). Overall, nylon-3 polymers are ineffective against species within the *Aspergillus* genus, regardless of the life form assayed (conidia or hyphae) for sensitivity.

###### 

MIC results for MM-TM, DM-TM, and NM against *Aspergillus* species[^a^](#ngtab2.1){ref-type="table-fn"}

  Species                       Cell type     Isolate           MIC~100~ (µg/ml)[^b^](#ngtab2.2){ref-type="table-fn"}                         
  ----------------------------- ------------- ----------------- ------------------------------------------------------- ---------- ---------- -----------
  **Aspergillus fumigatus**     **Conidia**   **AF293**         **\>64**                                                **\>64**   **\>64**   **\<1**
  **Aspergillus fumigatus**     **Conidia**   **CEA10**         **\>64**                                                **\>64**   **\>64**   **\<1**
                                **Hyphae**                      **\>64**                                                **\>64**   **\>64**   **8--16**
  **Aspergillus flavus**        **Conidia**   **NRRL3357**      **\>64**                                                **\>64**   **\>64**   **\<1**
                                **Hyphae**                      **\>64**                                                **\>64**   **\>64**   **\>64**
  **Aspergillus terreus**       **Conidia**   **NCCB IH2626**   **\>64**                                                **\>64**   **\>64**   **\<1**
                                **Hyphae**                      **\>64**                                                **\>64**   **\>64**   **\>64**
  **Aspergillus oryzae**        **Conidia**   **Rib40**         **\>64**                                                **\>64**   **\>64**   **1**
  **Aspergillus parasiticus**   **Conidia**   **Su-1**          **\>64**                                                **\>64**   **\>64**   **\<1**
  ***Neosartorya fischeri***    **Conidia**   **CBS 544.65**    **\>64**                                                **\>64**   **\>64**   **\>8**
  Aspergillus nidulans          Conidia       FGSCA4            16                                                      8          8          \<1
                                Hyphae                          \>64                                                    64         32         \>64
  Aspergillus aculeatus         Conidia       CBS 172.66        \>64                                                    \>64       8          \<1
  Aspergillus carbonarius       Conidia       DT0115-B6         64                                                      64         64         \<1
  Aspergillus wentii            Conidia       DT0136-E9         \>64                                                    64         32         \<1
  Aspergillus sydowii           Conidia       CBS 593.65        \>64                                                    64         64         2
  Aspergillus foetidus          Conidia       CBS 106.47        \>64                                                    64         32         2
  Aspergillus zonatus           Conidia       CBS 506.65        16                                                      8          8          \<1
  Aspergillus niger             Conidia       CBS 113.46        64                                                      32         32         \<1
  Aspergillus glaucus           Conidia       CBS 516.65        \>64                                                    64         32         2
  Aspergillus brasiliensis      Conidia       CBS 101740        64                                                      48         48         64
  Aspergillus clavatus          Conidia       CBS 513.65        \>64                                                    \>64       \>64       64
  Aspergillus versicolor        Conidia       CBS 795.97        16                                                      16         8          1

Note that the first six species (shown in boldface type) indicate that no reduction in growth was observed after incubation with nylon-3 polymer. The remaining 12 species (shown in lightface type) indicate that some reduction in growth was noted in response to MM-TM, DM-TM, and NM, even when the MIC~100~s were \>64 µg/ml.

MIC~100~, MIC resulting in 100% reduction in growth.

ITRA, itraconazole.

NM, MM-TM, and DM-TM are active against phylogenetically diverse filamentous fungi. {#s1.3}
-----------------------------------------------------------------------------------

On the basis of our observation of low sensitivity of *Aspergillus* spp. toward the polymers as single agents, we hypothesized that nylon-3 polymers were intrinsically less effective against filamentous fungi relative to yeasts. To test this hypothesis, we assessed MM-TM, DM-TM, and NM activity against 10 genera of filamentous fungi, following the CLSI M38-A2 methodology (conidia in liquid culture) or a modified CLSI method (hyphal fragments in liquid culture). Surprisingly, MM-TM, DM-TM, and NM were very active against phylogenetically diverse filamentous fungi, with MIC~100~ values of 4 to 8 µg/ml ([Table 3](#tab3){ref-type="table"}). The polymers were much more effective against medically relevant Rhizopus arrhizus (a causative agent of mucormycosis), the emerging pathogen Paecilomyces variotii ([@B30]), and Fusarium oxysporum isolates (which, along with A. flavus, is a serious agent of keratitis \[[@B31]\]) than they were against *Aspergillus* spp. Notably, all three nylon-3 polymers were active against *Scedosporium* spp., both Scedosporium apiospermum and *Scedosporium prolificans*. The latter species is an emerging fungal pathogen of both immunocompetent and immunocompromised individuals that is intrinsically resistant to most antifungal drugs (voriconazole \[VOR\] MIC~100~ \> 16 µg/ml); S. prolificans infections are often fatal ([@B32]).

###### 

MIC results for MM-TM, DM-TM, and NM against filamentous fungi

  Species                                                           Cell type   Isolate                                   MIC~100~ (µg/ml)[^a^](#ngtab3.1){ref-type="table-fn"}                              
  ----------------------------------------------------------------- ----------- ----------------------------------------- ------------------------------------------------------- ------ ------ ------------ ----
  Penicillium expansum                                              Conidia     d1                                        \>64                                                    \>64   64     1 (I)        
                                                                    Hyphae                                                \>64                                                    \>64   64     \>64 (I)     
  Talaromyces marneffei                                             Conidia     FRR2161                                   64                                                      32     8      0.125 (I)    
  Paecilomyces variotii                                             Conidia     QC[^e^](#ngtab3.4){ref-type="table-fn"}   4                                                       8      4      0.125 (V)    
  Fusarium oxysporum                                                Conidia     FO1                                       4                                                       8      8      4 (V)        
  Fusarium oxysporum                                                Conidia     FO~2~                                     8                                                       8      8      4 (V)        
  Fusarium oxysporum                                                Conidia     FO3                                       4                                                       8      4      \>16 (V)     
  Scedosporium apiospermum                                          Conidia     SA1                                       2                                                       8      4      1 (V)        
  Scedosporium apiospermum                                          Conidia     SA2                                       4                                                       4      4      1 (V)        
  Scedosporium prolificans                                          Conidia     LP1                                       4                                                       4      4      \>16 (V)     
  Rhizopus arrhizus                                                 Conidia     RA1                                       16                                                      8      4      0.5 (P)      
  Rhizopus arrhizus                                                 Conidia     RA2                                       8                                                       8      8      0.5 (P)      
  Rhizopus arrhizus                                                 Conidia     RA3                                       8                                                       8      8      0.5 (P)      
  Pseudogymnoascus destructans                                      Conidia     ATC MYA-4855                              4--8                                                    2--4   2--4   0.13 (I)     
  Trichophyton rubrum                                               Hyphae      ATCC 28188                                \>64                                                    64     16     0.5 (I)      
  Trichophyton tonsurans                                            Hyphae      CBS 112818                                16                                                      8      8      0.13 (I)     
  Microsporum canis                                                 Hyphae      UW10                                      16                                                      8      16     \<0.13 (I)   
  Filobasidiella depauperata[^d^](#ngtab3.5){ref-type="table-fn"}   Conidia     CBS 7855                                  \>64                                                    \>64   \>64   1 (I)        32
                                                                    Hyphae                                                \>64                                                    \>64   \>64                32

MIC~100~, MIC resulting in 100% reduction in growth.

The MICs for posaconazole (POS), voriconazole (VOR), or itraconazole (ITRA) are shown followed by the drug abbreviation in parentheses: I, itraconazole; V, voriconazole; P, posaconazole.

FLU, fluconazole.

MIC assays conducted in SD medium, rather than RPMI 1640.

QC, quality control.

For the dermatophytes Trichophyton tonsurans, Trichophyton rubrum, and Microsporum canis, MIC~100~ values were determined as the concentration of the agent required to halt hyphal growth, monitored as an increase in OD~600~, after 4 days of incubation at 29°C in RPMI 1640. Mixed efficacy of the nylon-3 polymers was observed across the three species of dermatophytes tested. The highest levels of antifungal activity were observed against T. tonsurans and M. canis (8 to 16 µg/ml), and the lowest levels were observed against T. rubrum (16 to 64 µg/ml) ([Table 3](#tab3){ref-type="table"}). The MIC~100~ of the dermatophyte Pseudogymnoascus destructans was evaluated after 7 days of incubation of conidia at 12°C in RPMI 1640. The activity against P. destructans, the causative agent of white nose syndrome in bats ([@B33]), is encouraging because there are limited options for preventing the spread of this devastating pathogen. The facility with which nylon-3 structure can be varied could provide opportunities for the development of topical agents with high specificity for particular fungi.

Strikingly, nylon-3 polymers were ineffective against Filobasidiella depauperata (MIC~100~ \> 64 µg/ml \[[Table 3\]](#tab3){ref-type="table"}), which is closely related to C. neoformans and grows exclusively as filaments ([@B34]). Resistance of F. depauperata to nylon-3 polymers was surprising because of the close phylogenetic relationship between C. neoformans and F. depauperata and the consistent sensitivity of C. neoformans isolates. F. depauperata spores and hyphae were both strongly resistant to polymer in SD medium (synthetically defined, minimal medium) ([@B35]); this species of fungi did not grow in the RPMI 1640 growth medium specified by CLSI methods. C. neoformans JEC20x21 spores and yeasts were both sensitive to all three polymers in SD medium (see [Tables S1](#tabS1){ref-type="supplementary-material"} and [S2](#tabS2){ref-type="supplementary-material"} in the supplemental material). As this level of inactivity against germinating conidia was reminiscent of the results observed with *Aspergillus* species, we asked whether the nylon-3 polymer MM-TM could act synergistically with an azole to inhibit germination of F. depauperata conidia, as had previously been observed with various A. fumigatus isolates. The copolymer MM-TM exhibited strong synergy (ΣFIC \[fractional inhibitory concentration\] index value of 0.04) with itraconazole against the azole-sensitive strain CBS 7855, resulting in \>20-fold decreases in azole and polymer MIC~100~s when the polymers are given in combination ([Table 4](#tab4){ref-type="table"}). The MM-TM copolymer was previously shown to act synergistically with azole-sensitive strains of A. fumigatus ([@B22]). Overall, all three nylon-3 polymers demonstrated strong activity against filamentous fungi spanning the fungal tree of life, with the notable exceptions of F. depauperata and the *Aspergillus* genus.

###### 

Synergy checkboard results with azoles and MM-TM against germinating Filobasidiella depauperta (CBS 7855) conidia

  Test agent(s)   MIC~100~ (µg/ml)[^a^](#ngtab4.1){ref-type="table-fn"}   ΣFIC index[^b^](#ngtab4.2){ref-type="table-fn"}   FIC interpretation   
  --------------- ------------------------------------------------------- ------------------------------------------------- -------------------- -------------
  MM-TM           \>64[^c^](#ngtab4.3){ref-type="table-fn"}               1                                                 0.04                 Synergistic
  Itraconazole    1                                                       \<0.06[^d^](#ngtab4.4){ref-type="table-fn"}                            

MIC after 72 h for the compound(s) as a single agent or for the combination of the compounds.

FIC, fractional inhibitory concentration.

The high off-scale MIC value, \>64 µg/ml, was converted to the next highest concentration, 128 µg/ml, for calculation of the FIC index.

The low off-scale MIC value, \<0.06 µg/ml, was converted to the next lowest concentration, 0.03 µg/ml, for calculation of the FIC index.
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NM, MM-TM, and DM-TM are active against dimorphic fungi. {#s1.4}
--------------------------------------------------------

Given the sensitivity of yeasts and most filamentous fungi to NM, MM-TM, and DM-TM, we hypothesized that dimorphic fungi would be sensitive to nylon-3 polymers. The CLSI M38-A2 broth macrodilution method was used to test all three polymers against *Coccidioides*, *Blastomyces*, and *Histoplasma* germinating conidia ([@B36]). Each of these dimorphic fungi represents a significant health threat for humans, and the dimorphism of these fungi is an important feature for their pathogenicity ([@B37], [@B38]). Activity was assessed based on 80% inhibition of growth (MIC~80~per the CLSI M38-A2 standard); the positive control for these studies was voriconazole ([Table 5](#tab5){ref-type="table"}). MM-TM, DM-TM, and NM have MIC~80~ values of \<4 µg/ml for all strains of Histoplasma capsulatum, Blastomyces dermatitidis, and *Coccidioides* spp. assayed.

###### 

MIC results for MM-TM, DM-TM, and NM against dimorphic fungi

  Species                    Isolate   MIC~80~ (µg/ml)[^a^](#ngtab5.1){ref-type="table-fn"}             
  -------------------------- --------- ------------------------------------------------------ --- ----- -------
  *Coccidioides* sp.         Cocci1    1                                                      2   2     0.25
                             Cocci2    1                                                      2   2     0.125
                             Cocci3    0.5                                                    1   1     0.06
                             Cocci5    2                                                      2   1     0.125
                             Cocci6    1                                                      1   1     0.25
                             Cocci7    1                                                      1   1     0.125
                             Cocci8    1                                                      1   1     0.125
                             Cocci9    1                                                      2   2     1
                             Cocci10   1                                                      1   1     0.06
                                                                                                        
  Blastomyces dermatitidis   BD1       1                                                      2   1     ≤0.03
                             BD2       1                                                      2   1     ≤0.03
                             BD3       1                                                      2   1     0.5
                                                                                                        
  Histoplasma capsulatum     HC1       4                                                      2   1     ≤0.03
                             HC2       1                                                      1   0.5   0.25
                             HC3       4                                                      2   2     0.125
                             HC4       2                                                      2   1     0.06
                             HC5       2                                                      2   1     0.25
                             HC6       4                                                      2   1     0.125
                             HC7       2                                                      2   1     0.5
                             HC8       2                                                      1   1     0.25
                             HC9       4                                                      2   2     0.06
                             HC10      4                                                      2   2     0.06

MIC~80~, MIC required to halt 80% of growth.

VOR, voriconazole.

NM, MM-TM, and DM-TM have moderate antifungal activity against *Pneumocystis* spp. {#s1.5}
----------------------------------------------------------------------------------

*Pneumocystis* spp. are known to cause lethal pneumonia in immunocompromised patients and are particularly associated with AIDS patients. Relatively little is known about *Pneumocystis* spp., ranging from its life cycle to survival strategies within mammalian hosts, since there currently exists no way to culture these species in a laboratory setting. Antifungal activity of the three polymers was assessed against cryopreserved and characterized *Pneumocystis* spp. Fungal viability in the presence of each polymer was measured using an ATP production assay (ATP-liteM assay) after 24, 48, and 72 h of polymer exposure. Calculating percent ATP reduction for all samples allowed us to determine 50% inhibitory concentrations (IC~50~s) ([Table 6](#tab6){ref-type="table"} and [Tables S3](#tabS3){ref-type="supplementary-material"} and [S4](#tabS4){ref-type="supplementary-material"}). MM-TM and DM-TM exhibited moderate activity, with 72 h IC~50~ values ranging from 2 to 5 µg/ml. The homopolymer NM was less active against Pneumocystis murina compared to Pneumocystis carinii, with 72-h IC~50~ values of 15 and 3 µg/ml, respectively. These data illustrate that even noncanonical fungi with unusual adaptations and niches (*Pneumocystis* species were once thought to be protozoan parasites \[[@B39]\]) show sensitivity to nylon-3 polymers, expanding opportunities for the use of nylon-3 materials against diverse fungi.

10.1128/mSphere.00223-18.5

Pneumocystis carinii ATP-liteM results. Download TABLE S3, PDF file, 0.1 MB.

Copyright © 2018 Rank et al.

2018

Rank et al.

This content is distributed under the terms of the

Creative Commons Attribution 4.0 International license

.

10.1128/mSphere.00223-18.6

Pneumocystis murina ATP-liteM results. Download TABLE S4, PDF file, 0.1 MB.
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###### 

IC~50~ results for MM-TM, DM-TM, and NM against *Pneumocystis* spp.

  ------------------------------------------------------------------------------------------------------------------------------------
  Species                IC~50~ (µg/ml)[^a^](#ngtab6.1){ref-type="table-fn"}   Activity scale of day 3\         
                                                                               IC~50~ values (µg/ml)            
  ---------------------- ----------------------------------------------------- -------------------------- ----- ----------------------
  Pneumocystis carinii   3.4                                                   4.5                        4.8   Moderate (1.0--9.99)

  Pneumocystis murina    15                                                    3.8                        2.3   Slight (10.0--49.9)
  ------------------------------------------------------------------------------------------------------------------------------------

IC~50~, 50% inhibitory concentration.

DISCUSSION {#s2}
==========

Our data show that the nylon-3 polymers MM-TM, DM-TM, and NM are effective against a surprisingly broad spectrum of fungi ([Fig. 2](#fig2){ref-type="fig"}), with only low to moderate toxicity toward mammalian cells (see [Text S1](#textS1){ref-type="supplementary-material"} and [Tables S5](#tabS5){ref-type="supplementary-material"} and [S6](#tabS6){ref-type="supplementary-material"} in supplemental material). Here we were able to assess sensitivity of 18 pathogenic genera toward the nylon-3 chemotype, based on measurements with 41 species and 72 isolates. Visualization of our results in the context of fungal phylogeny indicates general sensitivity to the polymers, with notable exceptions in the *Aspergillus* clade and the basidiomycete Filobasidiella depauperata ([Fig. 2](#fig2){ref-type="fig"}). Overall, these data provide support for the idea that nylon-3 polymers could be useful as broad-action therapeutic agents.

![Maximum likelihood phylogeny of fungal species used in this study. Species were color coded based on their general sensitivity to MM-TM, DM-TM, and NM nylon-3 polymers. All three polymers showed roughly equivalent activity against highly diverse fungi across the fungal kingdom. Any strain for which polymer activity was not equivalent across all three polymers is indicated by the pound symbol. Any species assessed in this study in which a different strain was used to compose the phylogeny tree is indicated by an asterisk. The strain tested in a previous publication ([@B11]) is indicated by a caret. N/A, not available.](sph0031825510002){#fig2}
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Activity of the nylon-3 polymers was observed against several species of fungi with limited or ineffective treatment options. For instance, the nylon-3 polymers were active against Rhizopus arrhizus, one of the causative agents of mucormycosis, which is a life-threatening disease in both immunocompetent and immunocompromised patients ([@B40]). Depending on the predisease status of the patient and route of infection, mucormycosis may present in pulmonary, rhino-orbital-cerebral, cutaneous, gastrointestinal, or disseminated forms. Treatment of mucormycosis often requires administration of amphotericin B after surgical debridement of necrotic tissues ([@B40]). Even with rigorous treatment regimes, mortality rates are high (\>40%), and amphotericin B toxicity is problematic for patients. The sensitivity of R. arrhizus to nylon-3 polymers suggests a new strategy to combat a challenging and deadly fungal disease for which current treatment options are highly limited ([@B40]).

All three nylon-3 polymers also showed efficacy against dermatophytes as preestablished hyphae. It is estimated that 20 to 25% of the world's population has skin mycoses ([@B41]), and while these infections are often superficial and cosmetic in nature, they can have severe impact on quality of life. Topical treatment of dermatophyte infections relies mostly on two classes of antifungal drugs, the azoles (e.g., fluconazole and ketoconazole) and the allylamines (e.g., terbinafine and naftifine). However, there have been increasing incidences of resistant and refractory dermatophyte infections in the clinic, and daily dosages of terbinafine can reach 1,000 mg ([@B42], [@B43]). Nylon-3 polymers, with their ease of synthesis and low anticipated cost of production, could provide a viable option for treating such topical fungal infections.

Comparisons between sensitive and resistant genera may ultimately enable us to identify the origin(s) of sensitivity and to elucidate mechanisms of nylon-3 action. A particular opportunity to understand how nylon-3 polymers confer antifungal activity emerges from the observation that these materials were ineffective against Filobasidiella depauperata, despite the polymers' strong activity against closely related *Cryptococcus* species. Since the polymers were active against other filamentous fungi, it is likely that properties not associated with filamentous morphology are responsible for this polymer resistance phenotype. Genetic comparisons of C. neoformans and F. depauperata may reveal insights into the mechanisms by which nylon-3 polymers exert their antifungal effects.

While all three nylon-3 polymers studied, NM, MM-TM, and DM-TM, had similar antifungal activities, subtle differences in activity profiles were noted throughout our phylogenetically broad analysis. NM was the most active polymer against the ascomycete yeasts *Candida* and *Saccharomyces*, while DM-TM was the most potent polymer against filamentous fungi. Overall hydrophobicity represents one of the main chemical properties that varied among the polymers (NM \< MM-TM \< DM-TM). All subunits in NM bear a short cationic side chain. Therefore, this homopolymer therefore cannot display a large and well-defined hydrophobic surface, which is believed to be an important feature of host defense peptides (HDPs) and their synthetic mimics. The MM-TM and DM-TM copolymers, on the other hand, should manifest greater overall hydrophobicity relative to NM because there are one or two additional nonpolar CH~2~ units in the MM and DM cationic subunits relative to NM, and each of the copolymers contains 20 to 30% of the entirely hydrophobic TM subunit. The copolymer expected to be most hydrophobic, DM-TM, was the most active among the three against filamentous fungi; however, this enhanced activity comes at the cost of increased mammalian cell toxicity relative to MM-TM or NM ([Text S1](#textS1){ref-type="supplementary-material"} and [Tables S5](#tabS5){ref-type="supplementary-material"} and [S6](#tabS6){ref-type="supplementary-material"}). The subtle differences in antifungal activity across the three polymers suggest that increased overall hydrophobicity may be required to enhance activity against filamentous fungi, particularly of the *Aspergillus* clade. Polymers with increased hydrophobicity relative to those discussed here, however, may require additional design features to avoid enhanced toxicity toward eukaryotic cells. Here we present the activities of materials with a novel chemotype, nylon-3 polymers, against a varied array of fungi from across the fungal kingdom. The surprisingly broad spectrum of nylon-3 antifungal activities, including inhibition of difficult-to-treat human pathogens, offers promise for the development of polymeric compounds with therapeutically useful properties. The ease of synthesis and structural diversification of nylon-3 polymers provide a broad scope for future efforts to optimize activity against pathogenic fungi while limiting toxicity toward the host.

MATERIALS AND METHODS {#s3}
=====================

Polymer synthesis and characterization. {#s3.1}
---------------------------------------

All polymers and monomers were prepared using previously reported methods ([@B20][@B21][@B23]). Please see the supplemental material for more information about polymer synthesis and characterization methods ([Text S2](#textS2){ref-type="supplementary-material"} and [Table S7](#tabS7){ref-type="supplementary-material"}).
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CLSI M27-A3 protocol. {#s3.2}
---------------------

The MIC~100~ endpoint of each antifungal agent was determined as the lowest concentration to inhibit 100% of fungal growth compared to the no-drug control. MIC~100~ values for all yeasts assayed ([Table 7](#tab7){ref-type="table"}) were determined by the broth microdilution method according to the CLSI M27-A3 guidelines, with slight modifications ([@B25]). Briefly, fungal cells at a density of 0.5 × 10^3^ to 2.5 × 10^3^ cells/ml were incubated at 30 to 35°C in RPMI 1640 plus 0.145 M 3-(*N*-morpholino)propanesulfonic acid (MOPS) (pH 7.0) in 96-well plates with twofold serial dilutions of nylon-3 polymer or fluconazole (FLC) from 1 to 64 µg/ml. After 24 to 72 h, the optical density at 600 nm (OD~600~) of each well was measured using a microplate reader. Wells containing fungal cells with no drug and wells containing only RPMI 1640 were used as positive and blank controls, respectively. Percent cell growth was determined as \[(sample absorbance − blank absorbance)/(control absorbance − blank absorbance)\] × 100%. All values reported represent the average MIC~100~ value for more than two biological replicates and two or more technical replicates each. The average MIC~100~ value consistently fell within a twofold serial dilution of the concentration of each experimental replicate. Any modifications to this protocol for a specific species is listed in [Table 7](#tab7){ref-type="table"}.

###### 

Strains used in this study

  Species              Isolate or strain                 Source                                                                                                       Description                                                 Antifungal test[^a^](#ngtab7.1){ref-type="table-fn"}
  -------------------- --------------------------------- ------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------- -------------------------------------------------------------------------
  S. cerevisiae        W303 (ATCC 200060)                Lab strain, obtained from Catherine Fox lab                                                                  *leu2-3*,*112 trp1-1 can1-100 ura3-1 ade2-1 his3-11*,*15*   CLSI M27-A3, 1 mM uracil
  C. neoformans        CN1                               Cerebrospinal fluid; clinical isolate                                                                        Azole susceptible                                           CLSI M27-A3, tested by NIAID
                       CN2                               Popliteal lymph node; clinical isolate (animal)                                                              Fluconazole resistant                                       CLSI M27-A3, tested by NIAID
                       CN3                               Cerebrospinal fluid; clinical isolate                                                                        Fluconazole resistant                                       CLSI M27-A3, tested by NIAID
  C. amylolentus       CBS 6273                          Insect frass isolate, obtained from Joseph Heitman lab                                                                                                                   CLSI M27-A3
                       CBS 6039                          Insect frass isolate, obtained from Joseph Heitman lab                                                                                                                   CLSI M27-A3
  C. albicans          ATCC 90028 (CA1)                  Blood                                                                                                                                                                    CLSI M27-A3, tested by NIAID
                       CA2                                                                                                                                                                                                        CLSI M27-A3, tested by NIAID
                       CA3                               Blood                                                                                                        Azole resistant                                             CLSI M27-A3, tested by NIAID
  C. krusei            QC                                                                                                                                             CLSI QC isolate for susceptibility testing                  CLSI M27-A3, tested by NIAID
  C. auris             B11220                            Clinical isolate (Japan), obtained from David Andes lab                                                                                                                  CLSI M27-A3
                       C54039                            Clinical isolate (Columbia), obtained from David Andes lab                                                   Amphotericin B resistant                                    CLSI M27-A3
  *Coccidioides* sp.   Cocci1                            Unknown; NIAID preclinical testing services                                                                                                                              CLSI M38-A2, tested by NIAID
                       Cocci2                            Unknown; NIAID preclinical testing services                                                                                                                              CLSI M38-A2, tested by NIAID
                       Cocci3                            Unknown; NIAID preclinical testing services                                                                                                                              CLSI M38-A2, tested by NIAID
                       Cocci4                            Unknown; NIAID preclinical testing services                                                                                                                              CLSI M38-A2, tested by NIAID
                       Cocci5                            Unknown; NIAID preclinical testing services                                                                                                                              CLSI M38-A2, tested by NIAID
                       Cocci6                            Unknown; NIAID preclinical testing services                                                                                                                              CLSI M38-A2, tested by NIAID
                       Cocci7                            Unknown; NIAID preclinical testing services                                                                                                                              CLSI M38-A2, tested by NIAID
                       Cocci8                            Unknown; NIAID preclinical testing services                                                                                                                              CLSI M38-A2, tested by NIAID
                       Cocci9                            Unknown; NIAID preclinical testing services                                                                                                                              CLSI M38-A2, tested by NIAID
                       Cocci10                           Unknown; NIAID preclinical testing services                                                                                                                              CLSI M38-A2, tested by NIAID
  B. dermatitidis      BD1                               Unknown; NIAID preclinical testing services                                                                                                                              CLSI M38-A2, tested by NIAID
                       BD2                               Unknown; NIAID preclinical testing services                                                                                                                              CLSI M38-A2, tested by NIAID
                       BD3                               Unknown; NIAID preclinical testing services                                                                                                                              CLSI M38-A2, tested by NIAID
  H. capsulatum        HC1                               Unknown; NIAID preclinical testing services                                                                                                                              CLSI M38-A2, tested by NIAID
                       HC2                               Unknown; NIAID preclinical testing services                                                                                                                              CLSI M38-A2, tested by NIAID
                       HC3                               Unknown; NIAID preclinical testing services                                                                                                                              CLSI M38-A2, tested by NIAID
                       HC4                               Unknown; NIAID preclinical testing services                                                                                                                              CLSI M38-A2, tested by NIAID
                       HC5                               Unknown; NIAID preclinical testing services                                                                                                                              CLSI M38-A2, tested by NIAID
                       HC6                               Unknown; NIAID preclinical testing services                                                                                                                              CLSI M38-A2, tested by NIAID
                       HC7                               Unknown; NIAID preclinical testing services                                                                                                                              CLSI M38-A2, tested by NIAID
                       HC8                               Unknown; NIAID preclinical testing services                                                                                                                              CLSI M38-A2, tested by NIAID
                       HC9                               Unknown; NIAID preclinical testing services                                                                                                                              CLSI M38-A2, tested by NIAID
                       HC10                              Unknown; NIAID preclinical testing services                                                                                                                              CLSI M38-A2, tested by NIAID
  A. fumigatus         CEA10                             Nancy Keller lab                                                                                                                                                         CLSI M38-A2, 35°C
  A. flavus            NRRL3357                          Nancy Keller lab                                                                                                                                                         CLSI M38-A2, 35°C
  A. oryzae            Rib40                             JGI Genome Project                                                                                                                                                       CLSI M38-A2, 35°C
  A. terreus           NCCB IH2624                       JGI Genome Project                                                                                                                                                       CLSI M38-A2, 35°C
  A. parasiticus       Su-1                              JGI Genome Project                                                                                                                                                       CLSI M38-A2, 35°C
  N. fisheri           CBS 544.65                        JGI Genome Project                                                                                                                                                       CLSI M38-A2, 35°C
  A. nidulans          FGSCA4                            JGI Genome Project                                                                                                                                                       CLSI M38-A2, 35°C
  A. aculeatus         CBS 172.66                        JGI Genome Project                                                                                                                                                       CLSI M38-A2, 35°C
  A. carbonarius       DT0115-B6                         JGI Genome Project                                                                                                                                                       CLSI M38-A2, 35°C
  A. wentii            DT0136-E9                         JGI Genome Project                                                                                                                                                       CLSI M38-A2, 35°C
  A. sydowii           CBS 593.65                        JGI Genome Project                                                                                                                                                       CLSI M38-A2, 35°C
  A. foetidus          CBS 106.47                        JGI Genome Project                                                                                                                                                       CLSI M38-A2, 35°C
  A. zonatus           CBS 506.65                        JGI Genome Project                                                                                                                                                       CLSI M38-A2, 35°C
  A. niger             CBS 113.46                        JGI Genome Project                                                                                                                                                       CLSI M38-A2, 35°C
  A. glaucus           CBS 516.65                        JGI Genome Project                                                                                                                                                       CLSI M38-A2, 35°C
  A. brasiliensis      CBS 101740                        JGI Genome Project                                                                                                                                                       CLSI M38-A2, 35°C
  A. clavatus          CBS 513.65                        JGI Genome Project                                                                                                                                                       CLSI M38-A2, 35°C
  A. versicolor        CBS 795.97                        JGI Genome Project                                                                                                                                                       CLSI M38-A2, 35°C
  P. expansum          d1                                Apples from Israel in 2012                                                                                                                                               CLSI M38-A2, 29°C
  T. marneffei         FRR2161, CBS 334.59, ATCC 18224   ATCC                                                                                                                                                                     CLSI M38-A2, 29°C
  P. variotii          QC                                                                                                                                             CLSI QC isolate                                             CLSI M38-A2, tested by NIAID
  F. oxysporum         FO1                               Blood                                                                                                        Clinical isolate                                            CLSI M38-A2, tested by NIAID
                       FO~2~                             Bone                                                                                                         Clinical isolate                                            CLSI M38-A2, tested by NIAID
                       FO3                               Blood                                                                                                        Clinical isolate                                            CLSI M38-A2, tested by NIAID
  S. apiospermum       SA1                               Toe                                                                                                          Clinical isolate                                            CLSI M38-A2, tested by NIAID
                       SA2                               Elbow tissue                                                                                                 Clinical isolate                                            CLSI M38-A2, tested by NIAID
  L. prolificans       LP1                               Chest wound                                                                                                  Clinical isolate                                            CLSI M38-A2, tested by NIAID
  R. arrhizus          RA1                               Nose tissue                                                                                                  Clinical isolate                                            CLSI M38-A2, tested by NIAID
                       RA2                               Tissue upper extremity                                                                                       Clinical isolate                                            CLSI M38-A2, tested by NIAID
                       RA3                               Palate tissue                                                                                                Clinical isolate                                            CLSI M38-A2, tested by NIAID
  F. depauperata       CBS 7855                          Caterpillar isolate, obtained from Joseph Heitman lab                                                                                                                    CLSI M38-A2, SD was used as the growth medium during antifungal testing
  T. rubrum            ATCC 28188                        Alana Sterkel lab; UW[^b^](#ngtab7.2){ref-type="table-fn"} Department of Pathology and Laboratory Medicine   Clinical isolate; nail                                      CLSI M38-A with modifications[^c^](#ngtab7.3){ref-type="table-fn"}
  M. canis             UW10                              Karen Moriello lab; UW School of Veterinary Medicine                                                         Wild-animal isolate; cat                                    CLSI M38-A with modifications[^c^](#ngtab7.3){ref-type="table-fn"}
  T. tonsurans         CBS 112818                        Theodore White lab, Broad Institute                                                                          Clinical isolate; cheek                                     CLSI M38-A with modifications[^c^](#ngtab7.3){ref-type="table-fn"}
  P. destructans       ATCC MYA-4855                     Jeffrey Lorch lab; U.S. Geological Survey                                                                    Wild-animal isolate; bat                                    CLSI M38-A with modifications[^c^](#ngtab7.3){ref-type="table-fn"}

The antifungal test and modifications are given. NIAID, National Institute of Allergy and Infectious Diseases.

UW, University of Wisconsin.

CLSI M38-A with modifications to test established hyphae rather than conidia for susceptibility. See the paragraph on the revised CLSI M38-A protocol for hyphae of filamentous fungi and dermatophytes in Materials and Methods.

Revised CLSI M38-A protocol for hyphae of filamentous fungi and dermatophytes. {#s3.3}
------------------------------------------------------------------------------

The MIC~100~ endpoint of each antifungal agent was determined as the lowest concentration to inhibit 100% of hyphal growth. MIC~100~ values for all filamentous fungi assayed were determined by the broth microdilution method according to CLSI M38-A guidelines, with modifications ([@B44]).

For the dermatophytes, crushed hyphal fragments of Trichophyton tonsurans, Trichophyton rubrum, and Microsporum canis at a density corresponding to an OD~600~ reading of 0.05 were incubated at 29°C in RPMI 1640 plus 0.145 M MOPS, pH 7.0, in 96-well plates with twofold serial dilutions of nylon-3 polymer or with itraconazole (ITRA) from 1 to 64 µg/ml. After 96 h, the MIC of each well was measured by monitoring the changes in OD~600~compared to the value at the 0-h time point. From the OD measurements, a difference in OD greater than 0.03 from the values at the 96- and 0-h time points was indicative of growth. All values reported represent the average MIC~100~value for two biological replicates and six technical replicates each. The average MICs consistently fell within a twofold serial dilution of the concentration of each experimental replicate.

Pseudogymnoascus destructans at a density of 1 × 10^4^ spores/ml was incubated at 12°C in RPMI 1640 plus 0.145 M MOPS, pH 7.0, in 96-well plates with twofold serial dilutions of nylon-3 polymer or with ITRA from 1 to 64 µg/ml. After 96 h, the MIC of each well was measured by monitoring changes in OD~600~compared to the value at the 0-h time point. From the OD measurements, a difference in OD greater than 0.01 from the values at the 120- and 0-h time points was indicative of growth. All values reported represent the average MIC~100~ value for two biological replicates and six technical replicates each. The average MICs consistently fell within a twofold serial dilution of the concentration of each experimental replicate.

A total of 1 × 10^4^ conidia/ml of Aspergillus fumigatus, Aspergillus terreus, Aspergillus flavus, or Aspergillus nidulans were inoculated into RPMI 1640 plus 0.145 M MOPS, pH 7.0 in 96-well plates and incubated at 37°C for 18 to 24 h to allow for growth of the extensive hyphal network. Hyphae were then treated with twofold serial dilutions of nylon-3 polymer or with ITRA from 1 to 64 µg/ml and allowed to incubate at 37°C. OD~600~ readings were obtained at 0, 24, and 48 h. From the OD measurements, a difference in OD greater than 0.05 from the values at the 48- and 0-h time points was indicative of growth. All values reported represent the average MIC~100~ value for two biological replicates and six technical replicates each. The average MICs consistently fell within a twofold serial dilution of the concentration of each experimental replicate.

A total of 1 × 10^4^ spores/ml of Penicillium expansum conidia were inoculated into RPMI 1640 plus 0.145 M MOPS, pH 7.0, in 96-well plates and incubated at room temperature for 24 to 48 h to allow for germination into established hyphae. Hyphae were then treated with twofold serial dilutions of nylon-3 polymer or with ITRA from 1 to 64 µg/ml and allowed to incubate further at room temperature. OD~600~ readings were obtained at 0, 24, and 48 h. After 48 h, the MIC of each well was measured by monitoring changes in OD~600~ in comparison to the value at the 0-h time point. From the OD measurements, a difference in OD greater than 0.05 from the values at the 48- and 0-h time point was indicative of growth. All values reported represent the average MIC~100~ value for two biological replicates and six technical replicates each. The average MICs consistently fell within a twofold serial dilution of the concentration of each experimental replicate.

CLSI M38-A2 protocol. {#s3.4}
---------------------

The MIC~100~ endpoint of each antifungal agent was determined as the lowest concentration to inhibit 100% of hyphal outgrowth from conidia. The MIC~80~ endpoint of each antifungal was determined as the concentration to inhibit 80% of fungal growth. MIC~100~ or MIC~80~ values for all filamentous or dimorphic fungi assayed ([Table 7](#tab7){ref-type="table"}) were determined by the broth macrodilution method according to the CLSI M38-A2 guidelines, with slight modifications ([@B36]). Briefly, fungal cells at a density of 0.5 × 10^4^to 5 × 10^4^ conidia/ml were incubated at 35°C in RPMI 1640 plus 0.145 M MOPS, pH 7.0, in 96-well plates with twofold serial dilutions of the nylon-3 polymer or with fluconazole (FLC), voriconazole (VOR), or itraconazole (ITRA) from 1 to 64 µg/ml. After 24 to 72 h, the MIC of each well was measured visually using a dissecting microscope. All values reported represent the average MIC~100~ values for more than two biological replicates and two or more technical replicates each. The average MICs consistently fell within a twofold serial dilution of the concentration of each experimental replicate. Any modifications to this protocol for a specific species are listed in [Table 7](#tab7){ref-type="table"}.

ATP-liteM assay for *Pneumocystis* spp. {#s3.5}
---------------------------------------

Cryopreserved and characterized Pneumocystis carinii isolated from rat lung tissue and Pneumocystis murina isolated from mouse lung tissue were distributed into triplicate wells of 48-well plates with a final volume of 500 µl at a final concentration of 5 × 10^7^ nuclei/ml P. carinii and 5 × 10^6^ nuclei/ml P. murina. Controls and compounds were added and incubated at 36°C and 5% CO~2~. At 24, 48, and 72 h, 10% of the well volume was removed, and the ATP content was measured using PerkinElmer ATP-liteM luciferin-luciferase assay. The luminescence generated by the ATP content of the samples was measured by a BMG PolarStar optima spectrophotometer. A sample of each group was examined microscopically on the final assay day to rule out the presence of bacteria.

For 50% inhibitory concentration (IC~50~) calculations, background luminescence was subtracted, and triplicate well readings of duplicate assays were averaged. For each day's reading, percent reduction in ATP for all groups was calculated as follows: \[(medium control − experimental value)/medium control\] × 100. IC~50~ values were calculated using GraphPad Prism 6 linear regression program ([Tables S3](#tabS3){ref-type="supplementary-material"} and [S4](#tabS4){ref-type="supplementary-material"}).

Evolutionary analysis. {#s3.6}
----------------------

Multigene-based phylogeny between all fungal species depicted in [Fig. 2](#fig2){ref-type="fig"} was constructed based on amino acid sequences of 14 genes ([Table S8](#tabS8){ref-type="supplementary-material"}) identified in *Fusarium* spp. to be conserved for various energetic processes ([@B45]). Orthologous proteins for genes listed in [Table S8](#tabS8){ref-type="supplementary-material"} were identified in each species using HMMer (Ensembl Fungi). Ten genes from Wiemann et al. ([@B45]) were omitted from the analysis due to lack of orthologous protein identity in one or more of the species tested. Resulting protein sequences for each of the gene were aligned to well-conserved regions using MAFFT ([@B46]) and trimmed using Gblocks ([@B47]) using default parameters. All positions containing gaps and missing data were eliminated. Trimmed alignments were then concatenated for each species, and a maximum likelihood (ML) phylogeny was inferred based on the JTT model ([@B48]) using MEGA7 ([@B49]) and viewed in FigTree (<http://tree.bio.ed.ac.uk/software/figtree/>).

10.1128/mSphere.00223-18.10

Fourteen genes used for evolutionary analysis of all fungal species depicted in [Fig. 2](#fig2){ref-type="fig"} of the article. Download TABLE S8, PDF file, 0.1 MB.

Copyright © 2018 Rank et al.

2018

Rank et al.

This content is distributed under the terms of the

Creative Commons Attribution 4.0 International license

.

Data availability. {#s3.7}
------------------

All data are included in the article and supplemental files.
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